The potential use of ebselen in treatment-resistant depression

The potential use of ebselen in treatment-resistant depression

Ebselen is an organoselenium compound developed as an antioxidant and subsequently shown to be a glutathione peroxidase (GPx) mimetic. Ebselen shows some efficacy in post-stroke neuroprotection and is currently in trial for the treatment and prevention of hearing loss, Meniere’s Disease and severe a...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Ramli, FF, Cowen, PJ, Godlewska, BR
Natura:	Journal article
Lingua:	English
Pubblicazione:	MDPI 2022

Documenti analoghi

The Potential Use of Ebselen in Treatment-Resistant Depression
di: Fitri Fareez Ramli, et al.
Pubblicazione: (2022-04-01)

Effects of ebselen addition on emotional processing and brain neurochemistry in depressed patients unresponsive to antidepressant medication
di: Ramli, FF, et al.
Pubblicazione: (2024)

Investigating the effects of the lithium-mimetic drug, ebselen, on emotional processing and brain neurochemistry in patients with medication-resistant depression
di: Ramli, FF
Pubblicazione: (2024)

Effects of the potential lithium-mimetic, ebselen, on impulsivity and emotional processing
di: Masaki, C, et al.
Pubblicazione: (2016)

Effects of ebselen addition on emotional processing and brain neurochemistry in depressed patients unresponsive to antidepressant medication
di: Fitri Fareez Ramli, et al.
Pubblicazione: (2024-05-01)

Behavioural characterisation of ebselen; a potential lithium-mimetic
di: Singh, N, et al.
Pubblicazione: (2014)

Effects of the potential lithium-mimetic, ebselen, on brain neurochemistry: a magnetic resonance spectroscopy study at 7 tesla
di: Masaki, C, et al.
Pubblicazione: (2016)

Ebselen as a novel IMPase inhibitor as a lithium mimetic
di: Churchill, G, et al.
Pubblicazione: (2014)

The putative lithium-mimetic ebselen reduces impulsivity in rodent models
di: Barkus, C, et al.
Pubblicazione: (2018)

Repurposing Clinical Molecule Ebselen to Combat Drug Resistant Pathogens.
di: Shankar Thangamani, et al.
Pubblicazione: (2015-01-01)

Stress, inflammation and hippocampal subfields in depression: A 7 tesla MRI study
di: Tannous, J, et al.
Pubblicazione: (2020)

Translating the promise of 5HT4 receptor agonists for the treatment of depression
di: Murphy, SE, et al.
Pubblicazione: (2020)

Investigating the neurochemistry of depression and the novel mood stabilising agent, ebselen, using magnetic resonance spectroscopy
di: Masaki, C
Pubblicazione: (2016)

Ebselen Optimized the Therapeutic Effects of Silver Nanoparticles for Periodontal Treatment
di: Liang Y, et al.
Pubblicazione: (2023-12-01)

Predicting treatment response in depression: the role of anterior cingulate cortex
di: Godlewska, BR, et al.
Pubblicazione: (2018)

Is Ebselen A Therapeutic Target in Fracture Healing?
di: Ahmet Kose, et al.
Pubblicazione: (2020-06-01)

Chemistry Related to the Catalytic Cycle of the Antioxidant Ebselen
di: Kai N. Sands, et al.
Pubblicazione: (2023-04-01)

Ebselen: A Promising Repurposing Drug to Treat Infections Caused by Multidrug-Resistant Microorganisms
di: Agostinho Alves de Lima e Silva, et al.
Pubblicazione: (2024-01-01)

Ebselen and Analogues: Pharmacological Properties and Synthetic Strategies for Their Preparation
di: Claudio Santi, et al.
Pubblicazione: (2021-07-01)

Ebselen Interferes with Alzheimer’s Disease by Regulating Mitochondrial Function
di: Xuexia Li, et al.
Pubblicazione: (2022-07-01)

Convergent Synthesis of Two Fluorescent Ebselen-Coumarin Heterodimers
di: Jim Küppers, et al.
Pubblicazione: (2016-07-01)

Effect of the putative lithium mimetic ebselen on brain myo-inositol, sleep, and emotional processing in humans
di: Singh, N, et al.
Pubblicazione: (2016)

Effect of the Putative Lithium Mimetic Ebselen on Brain Myo-Inositol, Sleep, and Emotional Processing in Humans
di: Singh, N, et al.
Pubblicazione: (2015)

Cognitive neuropsychological theory of antidepressant action: A modern-day approach to depression and its treatment
di: Godlewska, BR, et al.
Pubblicazione: (2020)

Synergistic antibacterial effect of silver and ebselen against multidrug‐resistant Gram‐negative bacterial infections
di: Lili Zou, et al.
Pubblicazione: (2017-06-01)

Metallocenyl derivatives of ebselen are selective and competitive inhibitors of thioredoxin reductase
di: Koh, Wei Xiang, et al.
Pubblicazione: (2022)

The Effectiveness of Ebselen in Facial Nerve Crush Injury: An Experimental Study
di: Lütfü Şeneldir, et al.
Pubblicazione: (2024-11-01)

In Vitro Anti-Prostate Cancer Activity of Two Ebselen Analogues
di: Katarzyna B. Kaczor-Keller, et al.
Pubblicazione: (2020-03-01)

Neurochemistry of major depression: a study using magnetic resonance spectroscopy.
di: Godlewska, B, et al.
Pubblicazione: (2015)

In Vitro Efficacy of Ebselen and BAY 11-7082 Against Naegleria fowleri
di: Anjan Debnath, et al.
Pubblicazione: (2018-03-01)

The Assessment on Synergistic Activity of Ebselen and Silver Ion Against Yersinia pseudotuberculosis
di: Chuanjiang Dong, et al.
Pubblicazione: (2022-07-01)

Synthesis of new alkylated and methoxylated analogues of ebselen with antiviral and antimicrobial properties
di: Magdalena Piętka-Ottlik, et al.
Pubblicazione: (2017-02-01)

Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs
di: Wang Y, et al.
Pubblicazione: (2017-05-01)

Investigation of the neurochemical, molecular and behavioural properties of the putative lithium-mimetic, ebselen
di: Antoniadou, I
Pubblicazione: (2015)

Use of ebselen as a neuroprotective agent in rat spinal cord subjected to traumatic injury
di: Wojciech Slusarczyk, et al.
Pubblicazione: (2019-01-01)

Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients.
di: Godlewska, B, et al.
Pubblicazione: (2012)

Short-term SSRI treatment remediates amygdala hyperactivity in depressed patients
di: Godlewska, B, et al.
Pubblicazione: (2011)

Topical Therapeutic Efficacy of Ebselen Against Multidrug-Resistant Staphylococcus aureus LT-1 Targeting Thioredoxin Reductase
di: Chuanjiang Dong, et al.
Pubblicazione: (2020-01-01)

Drug treatment of tricyclic resistant depression
di: Chalmers, J, et al.
Pubblicazione: (1990)

The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI
di: Megan Garland, et al.
Pubblicazione: (2020-04-01)